Workflow
医汇集团(08161) - 2023 Q3 - 季度财报
MEDINET GROUPMEDINET GROUP(HK:08161)2023-02-10 12:57

Financial Performance - The group's revenue for the nine months ended December 31, 2022, was approximately HKD 83.5 million, a decrease of about HKD 14.6 million compared to the same period in 2021[9]. - The net loss attributable to the owners of the company for the nine months ended December 31, 2022, was approximately HKD 5.1 million, compared to a net loss of approximately HKD 1.6 million for the same period in 2021[9]. - For the three months ended December 31, 2022, the group's revenue was HKD 24.8 million, down from HKD 31.8 million in the same period of 2021, representing a decrease of approximately 22.5%[10]. - The group reported a pre-tax loss of HKD 5.2 million for the three months ended December 31, 2022, compared to a pre-tax loss of HKD 2.0 million for the same period in 2021[10]. - The total comprehensive loss for the nine months ended December 31, 2022, was HKD 5.5 million, compared to HKD 1.8 million for the same period in 2021[11]. - Basic loss per share for the nine months ended December 31, 2022, was HKD 12.17, compared to HKD 3.87 for the same period in 2021[11]. - The company incurred a loss of HKD 49,784,000 for the nine months ended December 31, 2022, compared to a loss of HKD 40,115,000 for the same period in 2021[19]. - The total comprehensive expense for the nine months ended December 31, 2022, was HKD 5,518,000, which includes a loss of HKD 5,063,000 and a foreign exchange difference of HKD 250,000[19]. Revenue Breakdown - Revenue from medical services provided to contract clients was HKD 20,183,000 for the nine months ended December 31, 2022, down 14.1% from HKD 23,548,000 in the previous year[20]. - Revenue from dental services provided to self-paying patients was HKD 45,476,000 for the nine months ended December 31, 2022, a decrease of 18% compared to HKD 55,475,000 for the same period in 2021[20]. - Revenue from medical plans provided to contract clients decreased from approximately HKD 23.5 million to approximately HKD 20.2 million, a decline of about 14.3%[31]. - Revenue from self-paying patients for medical services decreased from approximately HKD 14.4 million to approximately HKD 12.5 million, a decline of about 12.9%[32]. - Revenue from dental plans provided to contract clients increased from approximately HKD 4.7 million to approximately HKD 5.3 million, an increase of about 12.6%[32]. - Revenue from self-paying patients for dental services decreased from approximately HKD 55.5 million to approximately HKD 45.5 million, a decline of about 18.0%[34]. - Other income increased significantly from approximately HKD 1.0 million to approximately HKD 2.7 million, primarily due to additional income from the Hong Kong government's employment support scheme[35]. Expenses - The group incurred medical and dental professional service expenses of HKD 31.99 million for the nine months ended December 31, 2022, down from HKD 36.14 million in the same period of 2021[10]. - Employee costs for the nine months ended December 31, 2022, were HKD 29.03 million, a decrease from HKD 33.25 million in the same period of 2021[10]. - Medical and dental professional service expenses decreased from approximately HKD 36.1 million to approximately HKD 32.0 million, a decline of about 11.4%[36]. - Employee costs decreased from approximately HKD 33.3 million to approximately HKD 29.0 million, a decline of about 12.9%[37]. - Other expenses decreased from approximately HKD 10.7 million to approximately HKD 9.6 million, a decline of about 10.3%[44]. Dividends and Equity - The board of directors did not recommend the payment of an interim dividend for the nine months ended December 31, 2022[9]. - The company did not recommend any interim dividend for the nine months ended December 31, 2022, consistent with the previous year[24]. - The company’s total equity as of December 31, 2022, was HKD 31,120,000, a decrease from HKD 41,236,000 as of December 31, 2021[19]. Corporate Governance - The company has adopted a standard code of conduct for securities trading in compliance with GEM Listing Rules[59]. - The chairman and CEO roles are currently held by the same individual, which the board believes enhances strategic efficiency[56]. - No major shareholders or directors have reported any business interests that may compete with the company as of December 31, 2022[54]. - The company has complied with the applicable corporate governance code provisions throughout the reporting period[57]. - The company’s executive officers and directors have confirmed compliance with the trading regulations during the nine months ending December 31, 2022[59]. - The Audit Committee was established on May 19, 2016, to oversee the appointment and independence of external auditors, as well as the effectiveness of the audit process[61]. - The Audit Committee consists of three independent non-executive directors, including Mr. Leung Po-Hon as the chairman[61]. - The Group's unaudited condensed consolidated financial statements for the nine months ended December 31, 2022, were reviewed by the Audit Committee[62]. Shareholding Structure - As of December 31, 2022, the major shareholders include Medinet International Limited with 23,400,000 shares, representing 56.25% of the issued share capital[52]. - NSD Capital Limited holds 7,800,000 shares, accounting for 18.75% of the issued share capital[52]. - The beneficial ownership of Medinet International Limited is fully held by Mr. Chan, who is also the sole director[48]. - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending December 31, 2022[55].